Penumbra to be Acquired by Boston Scientific for $14.5 Billion in Cash and Stock

summarizeResume

This filing announces a definitive merger agreement where Penumbra will be acquired by Boston Scientific. The acquisition price of $374.00 per share represents a significant premium over Penumbra's current trading price of $355.00, which is already above its 52-week high. This strong valuation, coupled with the acquisition, offers immediate and substantial value to shareholders. The transaction, valued at approximately $14.5 billion, is a major strategic move that will integrate Penumbra's thrombectomy and neurovascular products into Boston Scientific's portfolio. This event fundamentally alters the investment thesis for Penumbra, as it will cease to be an independent publicly traded entity upon closing. The deal is subject to customary closing conditions, including shareholder and regulatory approvals, and is expected to close in 2026.

check_boxEvenements cles

• Definitive Merger Agreement Announced

  Penumbra Inc. has entered into a definitive agreement to be acquired by Boston Scientific Corporation.

• Significant Transaction Value

  The acquisition is valued at approximately $14.5 billion, representing a major strategic move for both companies.

• Shareholder Consideration

  Penumbra shareholders will receive $374.00 per share, payable in a mix of approximately 73% cash and 27% Boston Scientific common stock, subject to proration.

• Premium Valuation

  The offer price of $374.00 per share provides a premium over the current stock price of $355.00, which is trading above its 52-week high.

auto_awesomeAnalyse

This filing announces a definitive merger agreement where Penumbra will be acquired by Boston Scientific. The acquisition price of $374.00 per share represents a significant premium over Penumbra's current trading price of $355.00, which is already above its 52-week high. This strong valuation, coupled with the acquisition, offers immediate and substantial value to shareholders. The transaction, valued at approximately $14.5 billion, is a major strategic move that will integrate Penumbra's thrombectomy and neurovascular products into Boston Scientific's portfolio. This event fundamentally alters the investment thesis for Penumbra, as it will cease to be an independent publicly traded entity upon closing. The deal is subject to customary closing conditions, including shareholder and regulatory approvals, and is expected to close in 2026.